# N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

> **NCT00843921** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Mendel Tuchman** · enrollment: 52 (actual)

## Conditions studied

- Inborn Errors of Metabolism

## Interventions

- **DRUG:** N-carbamylglutamate

## Key facts

- **NCT ID:** NCT00843921
- **Lead sponsor:** Mendel Tuchman
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2018-04-25
- **Final completion:** 2020-06-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843921, "N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00843921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*